{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:56:32Z","timestamp":1783702592890,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-024-03869-9","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T04:02:03Z","timestamp":1728705723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries"],"prefix":"10.1186","volume":"24","author":[{"given":"Jacqueline","family":"Pesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zia","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"de Courcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Chatterton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva Lauretta","family":"Birija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethan","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Govindarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,12]]},"reference":[{"issue":"1","key":"3869_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):1\u201319.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"3869_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475\u201390.","journal-title":"Lancet Neurol"},{"issue":"1","key":"3869_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","volume":"70","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000;70(1):327\u201334.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"3869_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","volume":"36","author":"MK Hehir","year":"2018","unstructured":"Hehir MK, Silvestri NJ. Generalized Myasthenia gravis: classification, clinical presentation, natural history, and Epidemiology. Neurol Clin. 2018;36(2):253\u201360.","journal-title":"Neurol Clin"},{"issue":"2","key":"3869_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","volume":"36","author":"C Barnett","year":"2018","unstructured":"Barnett C, Herbelin L, Dimachkie MM, Barohn RJ. Measuring clinical treatment response in Myasthenia Gravis. Neurol Clin. 2018;36(2):339\u201353.","journal-title":"Neurol Clin"},{"issue":"3","key":"3869_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.5498\/wjp.v12.i3.470","volume":"12","author":"L Yu","year":"2022","unstructured":"Yu L, Qiu L, Ran H, Ma Q, Lu Y-R, Liu W-B. Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients. World J Psychiatry. 2022;12(3):470\u201382.","journal-title":"World J Psychiatry"},{"issue":"6","key":"3869_CR7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve. 2022;65(6):630\u20139.","journal-title":"Muscle Nerve"},{"issue":"14","key":"3869_CR8","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1212\/WNL.0000000000012604","volume":"97","author":"M Petersson","year":"2021","unstructured":"Petersson M, Feresiadou A, Jons D, Ilinca A, Lundin F, Johansson R, et al. Patient-reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: cross-sectional analysis of the Swedish GEMG study. Neurology. 2021;97(14):e1382\u201391.","journal-title":"Neurology"},{"issue":"6","key":"3869_CR9","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, et al. Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol. 2022;269(6):3050\u201363.","journal-title":"J Neurol"},{"issue":"4","key":"3869_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CND.0000000000000257","volume":"20","author":"AN Boscoe","year":"2019","unstructured":"Boscoe AN, Xin H, L\u02bcItalien GJ, Harris LA, Cutter GR. Impact of Refractory Myasthenia gravis on Health-Related Quality of Life. J Clin Neuromuscul Dis. 2019;20(4):173\u201381.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"7","key":"3869_CR11","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487.","journal-title":"Neurology"},{"issue":"1","key":"3869_CR12","doi-asserted-by":"publisher","first-page":"e066445","DOI":"10.1136\/bmjopen-2022-066445","volume":"13","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Philips G, Paci S, Beauchamp J, Chiroli S, Quinn C, et al. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open. 2023;13(1):e066445.","journal-title":"BMJ Open"},{"issue":"3","key":"3869_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.pjnns.2017.12.012","volume":"52","author":"IM Rozmilowska","year":"2018","unstructured":"Rozmilowska IM, Adamczyk-Sowa MH, Czyzewski D. The Myasthenia gravis-specific activities of Daily Living scale as a useful outcome measure and in routine clinical management in Polish patients. Neurol Neurochir Pol. 2018;52(3):368\u201373.","journal-title":"Neurol Neurochir Pol"},{"issue":"12","key":"3869_CR14","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, Doslikova K, Davis VA, Karavali M, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 2023;39(12):1707\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"3869_CR15","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"3869_CR16","doi-asserted-by":"publisher","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"key":"3869_CR17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"3869_CR18","unstructured":"European Pharmaceutical Market Research Association. Code of Conduct 2021. https:\/\/www.ephmra.org\/sites\/default\/files\/2022-03\/2021%2520EPHMRA%2520Code%2520of%2520Conduct%25202.11.21.pdf. Accessed 7 July 2022."},{"key":"3869_CR19","unstructured":"US Department of Health & Human Services. Summary of the HIPAA Privacy Rule 2020. http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf. Accessed 7 July 2022."},{"key":"3869_CR20","unstructured":"US Department of Health & Human Services. Health Information Technology Act 2009. https:\/\/www.hhs.gov\/sites\/default\/files\/ocr\/privacy\/hipaa\/administrative\/enforcementrule\/enfifr.pdf?language=es. Accessed 7 July 2022."},{"issue":"5","key":"3869_CR21","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/mus.21142","volume":"38","author":"GI Wolfe","year":"2008","unstructured":"Wolfe GI, Barohn RJ, Sanders DB, McDermott MP. Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis. Muscle Nerve. 2008;38(5):1429\u201333.","journal-title":"Muscle Nerve"},{"issue":"3","key":"3869_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3233\/JND-200484","volume":"7","author":"RHP de Meel","year":"2020","unstructured":"de Meel RHP, Barnett C, Bril V, Tannemaat MR, Verschuuren J. Myasthenia Gravis Impairment Index: sensitivity for change in generalized muscle weakness. J Neuromuscul Dis. 2020;7(3):297\u2013300.","journal-title":"J Neuromuscul Dis"},{"key":"3869_CR23","doi-asserted-by":"crossref","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM, Composite MG et al. MG-ADL: Still a relevant outcome measure. Muscle & Nerve. 2011;44(5):727\u2009\u2013\u200931.","DOI":"10.1002\/mus.22140"},{"issue":"2","key":"3869_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jth.13908","volume":"16","author":"P Corraini","year":"2018","unstructured":"Corraini P, Sz\u00e9pligeti SK, Henderson VW, Ording AG, Horv\u00e1th-Puh\u00f3 E, S\u00f8rensen HT. Comorbidity and the increased mortality after hospitalization for stroke: a population-based cohort study. J Thromb Haemost. 2018;16(2):242\u201352.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3869_CR25","doi-asserted-by":"publisher","first-page":"18933","DOI":"10.1038\/s41598-021-98026-4","volume":"11","author":"S Kim","year":"2021","unstructured":"Kim S, Park J, Kwon JH, Oh AR, Gook J, Yang K, et al. The Charlson Comorbidity Index is associated with risk of 30-day mortality in patients with myocardial injury after non-cardiac surgery. Sci Rep. 2021;11(1):18933.","journal-title":"Sci Rep"},{"key":"3869_CR26","doi-asserted-by":"publisher","first-page":"117549","DOI":"10.1016\/j.jns.2021.117549","volume":"427","author":"SM Laakso","year":"2021","unstructured":"Laakso SM, Myllynen C, Strbian D, Atula S. Comorbidities worsen the prognosis of generalized myasthenia gravis post-thymectomy. J Neurol Sci. 2021;427:117549.","journal-title":"J Neurol Sci"},{"issue":"5","key":"3869_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/fampra\/cmr013","volume":"28","author":"LG Glynn","year":"2011","unstructured":"Glynn LG, Valderas JM, Healy P, Burke E, Newell J, Gillespie P, et al. The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. Fam Pract. 2011;28(5):516\u201323.","journal-title":"Fam Pract"},{"issue":"1","key":"3869_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.amjms.2016.03.004","volume":"352","author":"JS Williams","year":"2016","unstructured":"Williams JS, Egede LE. The Association between Multimorbidity and Quality of Life, Health Status and functional disability. Am J Med Sci. 2016;352(1):45\u201352.","journal-title":"Am J Med Sci"},{"issue":"1","key":"3869_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.21307\/ajon-2017-112","volume":"25","author":"T Keer-Keer","year":"2015","unstructured":"Keer-Keer T. The lived experience of adults with myasthenia gravis: a phenomenological study. Australasian J Neurosci. 2015;25(1):40\u20136.","journal-title":"Australasian J Neurosci"},{"issue":"2","key":"3869_CR30","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","volume":"10","author":"N Law","year":"2021","unstructured":"Law N, Davio K, Blunck M, Lobban D, Seddik K. The lived experience of Myasthenia gravis: a patient-led analysis. Neurol Ther. 2021;10(2):1103\u201325.","journal-title":"Neurol Ther"},{"key":"3869_CR31","doi-asserted-by":"publisher","first-page":"120268","DOI":"10.1016\/j.jns.2022.120268","volume":"437","author":"D Gelinas","year":"2022","unstructured":"Gelinas D, Parvin-Nejad S, Phillips G, Cole C, Hughes T, Silvestri N, et al. The humanistic burden of myasthenia gravis: a systematic literature review. J Neurol Sci. 2022;437:120268.","journal-title":"J Neurol Sci"},{"key":"3869_CR32","unstructured":"Myasthenia Gravis Foundation of America. What is Myasthenia Gravis? 2024 [ https:\/\/myasthenia.org\/Understanding-MG\/What-is-Myasthenia-Gravis"},{"issue":"2","key":"3869_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.5582\/irdr.2023.01003","volume":"12","author":"I Garc\u00eda","year":"2023","unstructured":"Garc\u00eda I, Mart\u00ednez O, L\u00f3pez-Paz JF, Salgueiro M, Rodr\u00edguez AA, Zorita J, et al. Health-related quality of life (HRQoL) and psychological impact of the COVID-19 pandemic on patients with myasthenia gravis. Intractable Rare Dis Res. 2023;12(2):88\u201396.","journal-title":"Intractable Rare Dis Res"},{"key":"3869_CR34","doi-asserted-by":"publisher","first-page":"e48430","DOI":"10.2196\/48430","volume":"10","author":"M Macaluso","year":"2024","unstructured":"Macaluso M, Rothenberg ME, Ferkol T, Kuhnell P, Kaminski HJ, Kimberlin DW, et al. Impact of the COVID-19 pandemic on people living with Rare diseases and their families: results of a National Survey. JMIR Public Health Surveill. 2024;10:e48430.","journal-title":"JMIR Public Health Surveill"},{"key":"3869_CR35","doi-asserted-by":"publisher","first-page":"263300402210826","DOI":"10.1177\/26330040221082673","volume":"3","author":"G Gutierrez","year":"2022","unstructured":"Gutierrez G, Girma H, Kuhnell P, Macaluso M, Kaminski HJ. Impact of the Covid-19 epidemic on a US sample of patients with myasthenia gravis. Ther Adv Rare Dis. 2022;3:26330040221082673.","journal-title":"Ther Adv Rare Dis"},{"issue":"2","key":"3869_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.46497\/ArchRheumatol.2020.7405","volume":"35","author":"F Abu Bakar","year":"2020","unstructured":"Abu Bakar F, Sazliyana Shaharir S, Mohd R, Mohamed Said MS, Rajalingham S, Wei Yen K. Burden of systemic Lupus Erythematosus on Work Productivity and Daily Living activity: a cross-sectional study among Malaysian multi-ethnic cohort. Arch Rheumatol. 2020;35(2):205\u201313.","journal-title":"Arch Rheumatol"},{"issue":"3","key":"3869_CR37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.berh.2013.07.009","volume":"27","author":"A Schmeding","year":"2013","unstructured":"Schmeding A, Schneider M. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2013;27(3):363\u201375.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"3869_CR38","doi-asserted-by":"publisher","first-page":"rkab029","DOI":"10.1093\/rap\/rkab029","volume":"5","author":"K Keramiotou","year":"2021","unstructured":"Keramiotou K, Anagnostou C, Konstantonis G, Kataxaki E, Sfikakis PP, Tektonidou MG. Impaired hand function and performance in activities of daily living in systemic lupus erythematosus, even in patients achieving lupus low disease activity state (LLDAS). Rheumatol Adv Pract. 2021;5(2):rkab029.","journal-title":"Rheumatol Adv Pract"},{"issue":"12","key":"3869_CR39","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1177\/09612033211045063","volume":"30","author":"A Kernder","year":"2021","unstructured":"Kernder A, D\u00fcsing C, Richter J, Brinks R, Fischer-Betz R, Winkler-Rohlfing B, et al. Factors detrimental to work productivity and daily activities in systemic lupus erythematosus patients - analysis of the German LuLa study. Lupus. 2021;30(12):1931\u20137.","journal-title":"Lupus"},{"key":"3869_CR40","doi-asserted-by":"publisher","first-page":"1068421","DOI":"10.3389\/fpsyg.2022.1068421","volume":"13","author":"A Ko\u0142tuniuk","year":"2022","unstructured":"Ko\u0142tuniuk A, Pawlak B, Kr\u00f3wczy\u0144ska D, Chojdak-\u0141ukasiewicz J. The quality of life in patients with multiple sclerosis - association with depressive symptoms and physical disability: a prospective and observational study. Front Psychol. 2022;13:1068421.","journal-title":"Front Psychol"},{"issue":"11","key":"3869_CR41","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1007\/s00415-015-7853-x","volume":"262","author":"S Tauhid","year":"2015","unstructured":"Tauhid S, Chu R, Sasane R, Glanz BI, Neema M, Miller JR, et al. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. J Neurol. 2015;262(11):2425\u201332.","journal-title":"J Neurol"},{"issue":"11","key":"3869_CR42","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.18553\/jmcp.2020.26.11.1424","volume":"26","author":"L Christopher-Stine","year":"2020","unstructured":"Christopher-Stine L, Wan GJ, Kelly W, McGowan M, Bostic R, Reed ML. Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use. JMCP. 2020;26(11):1424\u201333.","journal-title":"JMCP"},{"issue":"12","key":"3869_CR43","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1177\/1352458518796690","volume":"25","author":"CE van Munster","year":"2019","unstructured":"van Munster CE, D\u2019Souza M, Steinheimer S, Kamm CP, Burggraaff J, Diederich M, et al. Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis. Mult Scler. 2019;25(12):1673\u201381.","journal-title":"Mult Scler"},{"issue":"3","key":"3869_CR44","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/dme.12047","volume":"30","author":"C Saunders","year":"2013","unstructured":"Saunders C, Byrne CD, Guthrie B, Lindsay RS, McKnight JA, Philip S, et al. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med. 2013;30(3):300\u20138.","journal-title":"Diabet Med"},{"issue":"11","key":"3869_CR45","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world Clinical Data for the practicing clinician. Adv Ther. 2018;35(11):1763\u201374.","journal-title":"Adv Ther"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03869-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03869-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03869-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T16:03:17Z","timestamp":1728748997000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03869-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3869"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03869-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,12]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The MG DSP survey obtained ethics approval from the Western Institutional Review Board (sponsor protocol number: AG8768). Using a checkbox, patients provided informed consent to take part in the survey. Data were collected in such a way that patients and physicians could not be identified directly; all data were aggregated and de-identified before receipt. Data collection was undertaken in line with relevant legislation and guidelines including European Pharmaceutical Marketing Research Association guidelines [], the US Health Insurance Portability and Accountability Act 1996 [] and Health Information Technology for Economic and Clinical Health Act legislation [].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JP and ZC are employees of Janssen Scientific Affairs, LLC.\u00a0JdC, SB, GG, EC and SLB are employees of Adelphi Real World.\u00a0RG is on the advisory board for Argenx, UCB and Janssen and serves as speaker for Argenx and Alexion.\u00a0BH received payment as a contractor from Adelphi Real World for their involvement in this manuscript, and also receives payment as a contractor from Janssen (Pharmaceutical Companies of Johnson & Johnson), Amiculum Limited, and McCann Health Medical Communications.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"385"}}